Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Iotalamic Acid

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Iothalamic acid, 2276-90-6, 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid, 5-acetamido-2,4,6-triiodo-n-methylisophthalamic acid, Iotalamic acid [inn], Mi-216
    Molecular Formula
    C11H9I3N2O4
    Molecular Weight
    613.91  g/mol
    InChI Key
    UXIGWFXRQKWHHA-UHFFFAOYSA-N
    FDA UNII
    16CHD79MIX
    A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
    Iothalamic acid is a Radiographic Contrast Agent. The mechanism of action of iothalamic acid is as a X-Ray Contrast Activity.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
    2.1.2 InChI
    InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
    2.1.3 InChI Key
    UXIGWFXRQKWHHA-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I
    2.2 Other Identifiers
    2.2.1 UNII
    16CHD79MIX
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Acid, Iotalamic

    2. Acid, Iothalamic

    3. Acid, Methalamic

    4. Angio Conray

    5. Angio-conray

    6. Angioconray

    7. Conray 420

    8. Iodothalamate

    9. Iothalamate

    10. Iothalamate, Sodium

    11. Iothalamic Acid

    12. Iothalamic Acid, Calcium (2:1) Salt

    13. Iothalamic Acid, Monosilver (1+) Salt

    14. Iothalamic Acid, Monosodium Salt

    15. Iothalamic Acid, Monosodium Salt, Dimer

    16. Lopamidol

    17. Methalamic Acid

    18. Sodium Iothalamate

    2.3.2 Depositor-Supplied Synonyms

    1. Iothalamic Acid

    2. 2276-90-6

    3. 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic Acid

    4. 5-acetamido-2,4,6-triiodo-n-methylisophthalamic Acid

    5. Iotalamic Acid [inn]

    6. Mi-216

    7. Nsc-759891

    8. 16chd79mix

    9. 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic Acid

    10. Acidum Jotalamicum

    11. Acido Iotalamico

    12. Iothalamic Acid [usan]

    13. Acide Iotalamique

    14. Acidum Iotalamicum

    15. Acide Iotalamique [inn-french]

    16. Acido Iotalamico [inn-spanish]

    17. Acidum Iotalamicum [inn-latin]

    18. Einecs 218-897-4

    19. Mi 216

    20. Unii-16chd79mix

    21. Iothalamic Acid [usan:usp]

    22. Iothalamic-acid-d3

    23. Benzoic Acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-

    24. Iothalamic Acid (usp)

    25. Ec 218-897-4

    26. Iothalamate [vandf]

    27. Schembl38419

    28. Iotalamic Acid [jan]

    29. Iothalamic Acid [mi]

    30. Iotalamic Acid (jp17/inn)

    31. Iothalamicacid(200mg)

    32. Iotalamic Acid [mart.]

    33. Chembl1201300

    34. Dtxsid5023164

    35. Iotalamic Acid [who-dd]

    36. Schembl23630220

    37. Chebi:31713

    38. Iothalamic Acid [usp-rs]

    39. Hms3264d13

    40. Pharmakon1600-01503836

    41. Bcp13316

    42. Hy-b1053

    43. Zinc3830961

    44. Iotalamic Acid [ep Impurity]

    45. Nsc759891

    46. Akos025402283

    47. Benzoic Acid,3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]-

    48. Ac-7611

    49. Ccg-213208

    50. Cs-4575

    51. Db09133

    52. Iothalamic Acid [usp Monograph]

    53. Nsc 759891

    54. Ncgc00183042-01

    55. Ft-0740526

    56. D01258

    57. Ab01563288_01

    58. 276i906

    59. Sr-01000944232

    60. Q-201246

    61. Q6064129

    62. Sr-01000944232-1

    63. 5-acetylamino-2,4,6-triiodo-n-methyl-isophthalamic Acid

    64. 1-deoxy-1-(methylamino)-d-glucitol 5-acetamido-2,4,6 Triiodo-n-methylisophthalamate

    65. Benzoic Acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 613.91 g/mol
    Molecular Formula C11H9I3N2O4
    XLogP31.9
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count3
    Exact Mass613.7696 g/mol
    Monoisotopic Mass613.7696 g/mol
    Topological Polar Surface Area95.5 Ų
    Heavy Atom Count20
    Formal Charge0
    Complexity421
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Contrast Media

    Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    IOTHALAMIC ACID
    5.2.2 FDA UNII
    16CHD79MIX
    5.2.3 Pharmacological Classes
    Mechanisms of Action [MoA] - X-Ray Contrast Activity
    5.3 ATC Code

    V - Various

    V08 - Contrast media

    V08A - X-ray contrast media, iodinated

    V08AA - Watersoluble, nephrotropic, high osmolar x-ray contrast media

    V08AA04 - Iotalamic acid

    5.4 Absorption, Distribution and Excretion

    Absorption

    Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.

    Route of Elimination

    Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.

    5.5 Biological Half-Life

    In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.